Khodadoust MS, Rook AH, Porcu P, et al. - Through CITN-10, a single-arm, multicenter phase II trial of 24 patients with advanced mycosis fungoides (MF) or Sézary syndrome (SS), most prevalent subtypes of cutaneous T-cell lymphomas, researchers evaluated the effectiveness of pembrolizumab in patients with advanced relapsed or refractory MF or SS. Individuals were managed with pembrolizumab 2 mg/kg every 3 weeks for up to 24 months. In patients with advanced MF/SS, pembrolizumab exhibited an important antitumor activity with enduring responses and a desirable safety profile.